Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lokelma is a prescription potassium binder containing sodium zirconium cyclosilicate. It is indicated for treatment of hyperkalemia, or elevated blood potassium, in adults. Current packets contain 5 g or 10 g of powder that is mixed with water before administration. Lokelma is not used as emergency treatment for life-threatening hyperkalemia due to its delayed onset.
read more about lokelma ...Sodium zirconium cyclosilicate is a nonabsorbed compound that binds potassium in the gastrointestinal tract in exchange for hydrogen and sodium ions. Bound potassium is eliminated through the stool, reducing the amount of potassium in the body and lowering blood potassium concentrations.
Lokelma treats adults with hyperkalemia, including patients with chronic kidney disease or those receiving maintenance hemodialysis. Treatment is adjusted according to serum potassium measurements. Safety and efficacy in pediatric patients have not been established.
Initial treatment uses 10 g by mouth three times daily for up to 48 hours. Continued treatment usually starts at 10 g once daily, with a maintenance range of 5 g every other day to 15 g daily. Patients receiving chronic hemodialysis usually start at 5 g once daily on nondialysis days. Other oral medicines are generally taken at least two hours before or after Lokelma.
Lokelma contains sodium and can cause or worsen edema, particularly in patients with heart failure or kidney disease. Excessive potassium removal can cause hypokalemia, especially in patients receiving hemodialysis. Patients with severe constipation, bowel obstruction, or abnormal intestinal motility require special caution. Lokelma is radiopaque and can interfere with the interpretation of abdominal X-rays.
Lokelma treats hyperkalemia, or elevated blood potassium, in adults.
The recommended initial dose is 10 g three times daily for up to 48 hours.
Patients receiving chronic hemodialysis usually start at 5 g once daily on nondialysis days.
Yes. Lokelma contains sodium and can cause edema, particularly in patients susceptible to fluid retention.
DailyMed - LOKELMA (sodium zirconium cyclosilicate) powder, for suspension. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8833d6e6-33ab-4ea9-b78f-3ec30a904ef8. Date Accessed October 13, 2026.
LOKELMA Prescribing Information. AstraZeneca. https://medicalinformation.astrazeneca-us.com/prescribing-information/lokelma.html. Date Accessed October 13, 2026.
Sodium Zirconium Cyclosilicate. FDA Global Substance Registration System. https://precision.fda.gov/ginas/app/ui/substances/a1184b91-cdd6-45d4-b8a9-fecd30e887d3. Date Accessed October 13, 2026.
Sodium Zirconium Cyclosilicate. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a618035.html. Date Accessed October 13, 2026.
Sodium Zirconium Cyclosilicate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-Zirconium-Cyclosilicate. Date Accessed October 13, 2026.